A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)

  • STATUS
    Recruiting
  • End date
    Jun 27, 2025
  • participants needed
    185
  • sponsor
    Merck Sharp & Dohme LLC
Updated on 17 June 2022
cancer
measurable disease
carcinoma
breast cancer
growth factor
x-rays
metastasis
fluoropyrimidine
pembrolizumab
epidermal growth factor receptor
HER2
EGFR
pd-l1
trastuzumab
sorafenib
adenocarcinoma
solid tumor
metastatic solid tumor
stage iv breast cancer
solid neoplasm
hepatitis b antigen
triple-negative breast cancer

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies who receive V937 in Combination with Pembrolizumab (MK-3475). The primary objective for Part 1 is to evaluate the objective response rate, and the primary objective for Part 2 is to determine the safety and tolerability of V937 administered in combination with pembrolizumab.

Details
Condition Neoplasm Metastasis
Treatment Pembrolizumab, V937
Clinical Study IdentifierNCT04521621
SponsorMerck Sharp & Dohme LLC
Last Modified on17 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Locally-advanced disease that is not amenable to surgery or radiation, or Stage IV advanced/metastatic solid tumor malignancies
Histologically- or cytologically-confirmed diagnosis of an advanced/metastatic solid tumor
Measurable disease by RECIST 1.1 criteria as assessed by investigator. Target lesions in a previously irradiated area will be considered measurable if progression has been demonstrated in such lesions
Submitted a baseline tumor sample for analysis. Participants enrolling in Part 2 Cohorts D-F may enroll without submitting a tumor sample if all other enrollment criteria are met
Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale obtained within 72 hours prior to the first dose of study intervention
If participant has known human immunodeficiency virus (HIV)-positive disease, participant must have well-controlled HIV on antiretroviral therapy (ART), per study criteria
Adequate organ function
Male participants are eligible to participate if they agree to the following during the intervention period and for at least 120 days: Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR must agree to use contraception unless confirmed to be azoospermic
Female participants are eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies
Is not a woman of childbearing potential (WOCBP)
Is a WOCBP and using a contraceptive method that is highly effective, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days after the last dose of study intervention
Part 1, All Cohorts: participants must have at least one injectable lesion amenable to injection and/or biopsy
Contraceptive use by women should be consistent with local regulations regarding the
methods of contraception for those participating in clinical studies
Part 1, Cohort A
Locally recurrent, inoperable OR metastatic breast cancer treated with at least 1 prior line of therapy in the metastatic setting with skin involvement and/or subcutaneous lesions or accessible lymph nodes amenable to local injection. An exception would be allowed for participants who are not eligible to receive chemotherapy
Diagnosis of triple-negative breast cancer (estrogen receptor, progesterone receptor, and HER2-receptor negative status)
Part 1, Cohort B
Histologically confirmed advanced or metastatic head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, and/or larynx considered incurable and/or treated with no more than 1 previous line of therapy
Tumors must be PD-L1+
Documentation of HPV status for oropharyngeal cancers. Other HNSCC subtypes may submit HPV testing, but is not required
Part 1, Cohort C
Histologically confirmed cutaneous squamous cell carcinoma (cSCC) as the primary site of malignancy
Recurrent/metastatic disease only: Has metastatic disease defined as disseminated disease distant from the initial/primary site of diagnosis and/or with a history of locally-recurrent disease previously treated with surgery and/or radiotherapy, which is now incurable
Locally-advanced disease only: Must be ineligible for surgical resection per study criteria, and must have received prior radiation therapy to the index site or deemed ineligible for radiation therapy
Histologically-confirmed advanced/metastatic solid tumor that has progressed on all treatment known to confer clinical benefit
Part 2, Solid Tumors+Liver Metastases Dose Level 1-3 arms
Metastatic liver lesion(s) not exceeding one-third of the total liver volume AND a minimum of one injectable liver lesion
Part 2, Cohort D
Advanced hepatocellular carcinoma (HCC) following progression on, or intolerance to, sorafenib or lenvatinib with no curative options
Diagnosis of HCC confirmed by radiology, histology, or cytology
Child-Pugh Class A score
If a participant has a history of hepatitis C virus (HCV) infection, then he/she must have been successfully treated for this condition
Controlled (treated) hepatitis B participants will be allowed if they meet protocol-specified criteria
Participants who are anti-hepatitis B core (HBc) positive, negative for hepatitis B surface antigen (HBsAg), negative or positive for anti-hepatitis B surface (HBs), and who have an HBV viral load under 100 IU/mL, do not require HBV anti-viral prophylaxis
Histologically- or cytologically-confirmed diagnosis of locally advanced, unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Part 2, Cohort E
Received at least one prior line of therapy that includes a platinum/fluoropyrimidine doublet or triplet regimen
Had proven clinical progression 6 months following (or during) last dose of adjuvant or neo-adjuvant therapy
Human epidermal growth factor receptor 2 (HER2) negative status; or, those with HER2 positive status AND documented disease progression on a prior regimen containing trastuzumab

Exclusion Criteria

Chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) prior to first dose of study intervention, or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better
If major or minor surgery was performed at/near the area being considered for injection, participant must be recovered from toxicity and/or complications of intervention
If participant has had injection or radiation therapy, participant must be recovered from toxicity and/or complications of intervention
History of second malignancy, unless potentially curative treatment has been completed with no further evidence of malignancy
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with treated brain metastases may participate if lesions are radiologically stable
Active infection requiring therapy, except HIV criteria as stated above, and HBV and HCV criteria for HCC cohort as stated above
History of interstitial lung disease
History of noninfectious pneumonitis requiring active steroid therapy or ongoing pneumonitis
Active autoimmune disease that required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy
Known Hepatitis B or C infections or known to be positive for HBsAg/HBV deoxyribonucleic acid (DNA) or Hepatitis C Antibody or ribonucleic acid (RNA)
History of Kaposi's sarcoma and/or Multicentric Castleman's Disease
Known hypersensitivity to V937 and/or pembrolizumab or any of their excipients
Received prior therapy with anti-programmed cell death protein-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1) agents, Talimogene Laherparepvec (T-VEC), or any other oncolytic virus therapies
Received a live or live-attenuated vaccine within 30 days prior to first dose of study intervention. Administration of killed vaccines is allowed
Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention
Has had esophageal or gastric variceal bleeding within the last 6 months
Part 2, Cohort D
Has had clinically diagnosed hepatic encephalopathy in the 6 months prior to initiation of study intervention
Squamous cell or undifferentiated gastric cancer
Part 2, Cohort E
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note